Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19500204 | 0.91 | PRKCA (0.37) | PRKCAGRM1 | |
| SCHEMBL11750627 | 0.80 | ALDH1A1 (0.42) | PRKCATSHRCYP3A4ATMTDP1 | |
| SCHEMBL18067516 | 0.78 | TSHR (0.41) | PRKCATSHRCYP3A4TDP1GRM1 | |
| SCHEMBL19500212 | 0.76 | ALDH1A1 (0.50) | GRM1 | |
| SCHEMBL12306241 | 0.76 | ALDH1A1 (0.50) | GRM1 | |
| SCHEMBL12267797 | 0.73 | TSHR (0.37) | PRKCATSHRCYP3A4ATMTDP1 | |
| SCHEMBL20051874 | 0.73 | GRM1 (0.48) | TSHRTDP1GRM1 | |
| SCHEMBL19500206 | 0.73 | GRM1 (0.35) | PRKCATSHRGRM1 | |
| SCHEMBL19500079 | 0.72 | TSHR (0.37) | PRKCATSHR | |
| SCHEMBL12707569 | 0.72 | TSHR (0.32) | PRKCATSHRCYP3A4ATMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186808-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME LLC | 2018-07-05 | — | — | US | disclosed |
| US-9944654-B2 | Nargenicin compounds and uses thereof as antibacterial agents | MERCK SHARP & DOHME CORP. (US) | 2018-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186808-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | NRDC, MME, NME2 | PRKCA 4092/4885TSHR 4224/4885CYP3A4 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.